J Cancer 2017; 8(4):691-703. doi:10.7150/jca.17210 This issue Cite

Research Paper

Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy

Xing-Han Liu1*, Jun Lu2*, Wei Duan3, Zhi-Ming Dai4, Meng Wang1, Shuai Lin1, Peng-Tao Yang1, Tian Tian1, Kang Liu1, Yu-Yao Zhu1, Yi Zheng1, Qian-Wen Sheng1, Zhi-Jun Dai1✉

1. Department of Oncology, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China;
2. Clinical Research Center, First Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710061, China;
3. School of Medicine, Deakin University, Waurn Ponds, Victoria, Australia;
4. Department of Anesthesia, Second Affiliated Hospital of Xi'an Jiaotong University, Xi'an 710004, China.
* co-first authors

Citation:
Liu XH, Lu J, Duan W, Dai ZM, Wang M, Lin S, Yang PT, Tian T, Liu K, Zhu YY, Zheng Y, Sheng QW, Dai ZJ. Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy. J Cancer 2017; 8(4):691-703. doi:10.7150/jca.17210. https://www.jcancer.org/v08p0691.htm
Other styles

File import instruction

Abstract

The UGT1A1*28 polymorphism was suggested to be significantly connected with irinotecan-induced toxicity and response to chemotherapy. However, the results of previous studies are controversial. Hence we carried out a meta-analysis to investigate the effect of UGT1A1*28 polymorphism on severe diarrhea, neutropenia, and response of patients who had undergone irinotecan-based chemotherapy. The PubMed, Web of Science, Wanfang, and CNKI databases were searched for clinical trials assessing the association of UGT1A1*28 polymorphism with severe diarrhea, neutropenia, and response to irinotecan-based chemotherapy. The combined odds ratios (ORs) and 95% confidence intervals (CIs) were used to evaluate the relationship under a fixed- or random-effects model. Fifty-eight studies including 6087 patients with cancer were included. Our results showed that patients carrying the TA6/7 and TA7/7 genotypes had a greater prevalence of diarrhea and neutropenia than those with the TA6/6 genotype (TA6/7+TA7/7 vs. TA6/6: diarrhea, OR = 2.18, 95%CI = 1.68-2.83; neutropenia, OR = 2.15, 95%CI = 1.71-2.70), particularly patients with metastatic colorectal cancer. Stratified analysis showed that Asians with the TA6/7 and TA7/7 genotypes were more likely to have diarrhea and neutropenia, and Caucasians with the TA6/7 and TA7/7 genotypes were more likely to have neutropenia than other groups. However, patients with the TA6/7+TA7/7 genotypes showed a higher response than patients with TA6/6 genotype (OR = 1.20, 95%CI = 1.07-1.34), particularly Caucasians (OR = 1.23, 95%CI = 1.06-1.42) and patients with metastatic colorectal cancer (OR = 1.24, 95%CI = 1.05-1.48). Our data showed that the UGT1A1*28 polymorphism had a significant relationship with toxicity and response to irinotecan-based chemotherapy. This polymorphism may be useful as a monitoring index for cancer patients receiving irinotecan-based chemotherapy.

Keywords: UGT1A1*28, diarrhea, neutropenia, response.


Citation styles

APA
Liu, X.H., Lu, J., Duan, W., Dai, Z.M., Wang, M., Lin, S., Yang, P.T., Tian, T., Liu, K., Zhu, Y.Y., Zheng, Y., Sheng, Q.W., Dai, Z.J. (2017). Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy. Journal of Cancer, 8(4), 691-703. https://doi.org/10.7150/jca.17210.

ACS
Liu, X.H.; Lu, J.; Duan, W.; Dai, Z.M.; Wang, M.; Lin, S.; Yang, P.T.; Tian, T.; Liu, K.; Zhu, Y.Y.; Zheng, Y.; Sheng, Q.W.; Dai, Z.J. Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy. J. Cancer 2017, 8 (4), 691-703. DOI: 10.7150/jca.17210.

NLM
Liu XH, Lu J, Duan W, Dai ZM, Wang M, Lin S, Yang PT, Tian T, Liu K, Zhu YY, Zheng Y, Sheng QW, Dai ZJ. Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy. J Cancer 2017; 8(4):691-703. doi:10.7150/jca.17210. https://www.jcancer.org/v08p0691.htm

CSE
Liu XH, Lu J, Duan W, Dai ZM, Wang M, Lin S, Yang PT, Tian T, Liu K, Zhu YY, Zheng Y, Sheng QW, Dai ZJ. 2017. Predictive Value of UGT1A1*28 Polymorphism In Irinotecan-based Chemotherapy. J Cancer. 8(4):691-703.

This is an open access article distributed under the terms of the Creative Commons Attribution (CC BY-NC) license (https://creativecommons.org/licenses/by-nc/4.0/). See http://ivyspring.com/terms for full terms and conditions.
Popup Image